Santen Pharmaceutical has been granted a patent for a method to prevent or treat dry eye using olodaterol hydrochloride, a compound that does not significantly affect intraocular pressure. The patent includes the administration of a therapeutically effective amount of this compound to affected individuals. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of June 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of dry eye using olodaterol hydrochloride
A recently granted patent (US12005063B2) outlines a method for treating dry eye conditions through the administration of olodaterol hydrochloride. The claims specify that this treatment is particularly beneficial for subjects experiencing dry eye associated with various corneal and conjunctival epithelium disorders, including superficial punctate keratopathy, corneal ulcers, and keratoconjunctivitis sicca, among others. The patent also identifies specific causes of dry eye, such as tear film instability and lacrimal gland dysfunction, indicating a broad applicability of the treatment across different underlying conditions.
The claims further detail the administration parameters for olodaterol hydrochloride, emphasizing concentrations ranging from 0.00001% to 0.1% (w/v), with specific lower thresholds also noted. The method is designed for delivery in the form of eye drops, ensuring localized treatment. Importantly, the claims assert that the administration of olodaterol hydrochloride does not significantly alter intraocular pressure, which is a critical consideration in the management of eye conditions. This patent presents a novel approach to addressing dry eye symptoms, potentially offering a new therapeutic option for affected individuals.
To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
